The chemokine receptors CXCR4 and CXCR3 in cancer

Current Oncology Reports

Volumn 11, Issue 2, 2009, Pages 125-131

  Fulton, Amy M ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMD 4365; AMG 487; ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CTCE 9908; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PLERIXAFOR; TN 14003; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; DRUG TARGETING; GENE SILENCING; GENE TARGETING; GLIOMA; HEAD AND NECK CANCER; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MEDULLOBLASTOMA; MELANOMA; NEOPLASM; NONHUMAN; OSTEOSARCOMA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; RISK FACTOR; THYROID CANCER;

ANIMALS; BREAST NEOPLASMS; COLONIC NEOPLASMS; HUMANS; LIGANDS; MELANOMA; NEOPLASMS; RECEPTORS, CXCR3; RECEPTORS, CXCR4;

EID: 60349085081     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0019-1     Document Type: Review

References (39)

1. Graham GJ, Nibbs RJ: Lukacs NW. Totowa, NJ: Humana Press; 2007:31-54.
2. Muller A, Homey B, Soto H, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
3. Smith MCP, Luker KE, Gargow JR, et al.: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004, 64:8604-8612.
4. Balkwill F: The significance of the cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004, 14:171-179.
5. Scotten CJ, Wilson JL, Scott K, et al.: Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002, 62:5930-5938.
6. Tamamura H, Hori A, Kanzaki N, et al.: T140 analogs as CXCR4 antagonists identified as antimetastatic agents in the treatment of breast cancer. FEBS Lett 2003, 550:79-83.
7. Bertolini F, Dell'Agnola C, Mancuso P, et al.: CXCR4 neutralization a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002, 62:3106-3112.
8. Murakami T, Maki W, Cardones AR, et al.: Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002, 62:7328-7334.
9. Ben-Baruch A: Organ selectiRity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 2008, 25:345-356.
10. Zagzag D, Lukyanov Y, Lan L, et al.: Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: Implications for angiogenesis and glioma cell invasion. Lab Invest 2006, 86:1221-1232.
11. Akashi T, Koizumi K, Nagakawa O, et al.: Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep 2006, 16:831-836.
12. Sengupta S, Schiff R, Katzenellenbogen BS: Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Res Treat 2008 Sep 19 [Epub ahead of print].
13. Holland JD, Kochetkova M, Akekawatchai C, et al.: Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer. Cancer Res 2006, 66:4117-4124.
14. Serrati S, Margheri F, Fibbi G, et al.: Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression. J Pathol 2008, 214:545-554.
15. Akekawtchai C, Holland JD, Kochetkova M, et al.: Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. J Biol Chem 2005, 280:39701-39708.
16. Chinni SR, Yamamoto H, Dong Z, et al.: CXC12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 2008, 6:446-457.
17. Liang Z, Wu T, Lou H, et al.: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004, 64:4302-4308.
18. Yoon Y, Liang Z, Zhang X, et al.: CXC chemokine receptor-4-antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 2007, 15:7518-7524.
19. Rubin JB, Kung AL, Klein RS, et al.: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003, 100:13513-13518.
20. Yang L, Jackson E, Woerner BM, et al.: Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res 2007, 67:651-658.
21. Kim SY, Lee CH, Midura BV, et al.: Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008, 25:201-211.
22. Lasagni L, Francalanci M, Annunziato F, et al.: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003, 197:1537-1549.
23. Ehlert JE, Addison CA, Burdick MD, et al.: Identification and partial characterization of a variant of human CXR3 generated by posttranscriptional exon skipping. J Immunol 2004, 173:6234-6240.
24. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A: CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathologic prognostic factors. J Clin Pathol 2007, 60:596-599.
25. Kawada K, Hosogi H, Sonoshita M, et al.: Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007, 26:4679-4688.
26. Ma X, Norsworthy K, Kundu N, et al.: CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther, in press.
27. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM: The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000, 95:627-632.
28. Klatte T, Seligson DB, Leppert JT, et al.: The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol 2008, 179:61-66.
29. Kawada K, Sonoshita M, Sakashita H: Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004, 64:4010-4017.
30. Goldberg-Bittman L, Neumark E, Sagi-Assif O, et al.: The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett 2004, 92:171-178.
31. Goldberg-Bittman L, Sagi-Assif O, Meshel T, et al.: Cellular characteristics of neuroblastoma cells: Regulation by the ELR-CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine 2005, 29:105-117.
32. Datta D, Flaxenburg JA, Laxmanan S, et al.: Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: Relevance for the development of human breast cancer. Cancer Res 2006, 66:9509-9518.
33. Walser TC, Rifat S, Ma X, et al.: Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006, 66:7701-7707.
34. Zipin-Roitman A, Meshel T, Sagi-Assif O, et al.: CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007, 67:3396-3405.
35. Luster AD, Leder P: IP-10, a C-X-C chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993, 178:1057-1065.
36. Sgadari C, Angiolillo AL, Cherney BW, et al.: Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A 1996, 93:13791-13796.
37. Dorsey R, Kundu N, Yang Q, et al.: Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Res 2002, 62:2606-2610.
38. Walser TC, Ma X, Kundu N, et al.: Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model. J Immunother 2007, 30:490-498.
39. Winter D, Moser J, Kriehuber E, et al.: Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients. J Immunol 2007, 179:4272-4282.